Common Contracts
4 similar Selected Product License Agreement contracts by Artiva Biotherapeutics, Inc.
SELECTED PRODUCT LICENSE AGREEMENT (AB-101)Selected Product License Agreement • June 28th, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 21, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SELECTED PRODUCT LICENSE AGREEMENT (AB-201)Selected Product License Agreement • June 28th, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 29, 2020 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SELECTED PRODUCT LICENSE AGREEMENT (AB-201)Selected Product License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 29, 2020 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SELECTED PRODUCT LICENSE AGREEMENT (AB-101)Selected Product License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 21, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
